Chinese Upstart Ascletis Bags $100 Million in Series B Financing

Chinese biotech company Ascletis, which focuses on treatments of liver disease, scored $100 million in a Series B financing round. The company said it intends to use the proceeds to advance its pipeline as well as its sales force.

Beijing Mabworks Company Completes $39 Million Series B Funding

Beijing Mabworks Biotech, a gene engineering mAb company, raised $39 million for a Series B round, led by Shenzhen GTJA Investment Group. GTJA is a healthcare focused investment firm. Founded in...

Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Study Of Sulfatinib In...

Most biotechs start life with little money, one or several early-stage assets, a handful of employees and big dreams but face an uphill struggle to stay alive, let alone get to...

Ascentage Pharma Announces Series B Financing of RMB 500 Million to Advance Its Apoptosis-Targeted...

Ascentage Pharma, a global, clinical-stage biopharmaceutical company focused on apoptosis-targeted oncology drug discovery and development, has announced the completion of its Series B financing of RMB 500 million (equal to approximately $72...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...